These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Deferasirox for managing iron overload in people with thalassaemia. Bollig C, Schell LK, Rücker G, Allert R, Motschall E, Niemeyer CM, Bassler D, Meerpohl JJ. Cochrane Database Syst Rev; 2017 Aug 15; 8(8):CD007476. PubMed ID: 28809446 [Abstract] [Full Text] [Related]
3. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ. Cochrane Database Syst Rev; 2013 Aug 21; 2013(8):CD004450. PubMed ID: 23963793 [Abstract] [Full Text] [Related]
4. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload. Hagag AA, Hamam MA, Taha OA, Hazaa SM. Infect Disord Drug Targets; 2015 Aug 21; 15(2):98-105. PubMed ID: 26205801 [Abstract] [Full Text] [Related]
5. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study. Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK. Pediatr Blood Cancer; 2015 Sep 21; 62(9):1592-6. PubMed ID: 25820920 [Abstract] [Full Text] [Related]
7. Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study. DivakarJose RR, Delhikumar CG, Ram Kumar G. Indian J Pediatr; 2021 Apr 21; 88(4):330-335. PubMed ID: 32661609 [Abstract] [Full Text] [Related]
10. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial. Maggio A, Kattamis A, Felisi M, Reggiardo G, El-Beshlawy A, Bejaoui M, Sherief L, Christou S, Cosmi C, Della Pasqua O, Del Vecchio GC, Filosa A, Cuccia L, Hassab H, Kreka M, Origa R, Putti MC, Spino M, Telfer P, Tempesta B, Vitrano A, Tsang YC, Zaka A, Tricta F, Bonifazi D, Ceci A. Lancet Haematol; 2020 Jun 21; 7(6):e469-e478. PubMed ID: 32470438 [Abstract] [Full Text] [Related]
11. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand. Viprakasit V, Nuchprayoon I, Chuansumrit A, Torcharus K, Pongtanakul B, Laothamatas J, Srichairatanakool S, Pooliam J, Supajitkasem S, Suriyaphol P, Tanphaichitr VS, Tuchinda S. Am J Hematol; 2013 Apr 21; 88(4):251-60. PubMed ID: 23460233 [Abstract] [Full Text] [Related]
12. Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia. Merchant R, Ahmed J, Krishnan P, Jankharia B. Indian Pediatr; 2012 Apr 21; 49(4):281-5. PubMed ID: 21992861 [Abstract] [Full Text] [Related]
14. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran. Alavi S, Ebadi M, Ghazizadeh F, Arzanian MT, Shamsian B, Abdollah Gorji F. Pediatr Hematol Oncol; 2014 Feb 21; 31(1):76-86. PubMed ID: 24383712 [Abstract] [Full Text] [Related]
15. Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes. Yusuf S, Herdata HN, Edward ED, Khairunnisa K. F1000Res; 2023 Feb 21; 12():154. PubMed ID: 39233713 [Abstract] [Full Text] [Related]
16. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children. Gomber S, Saxena R, Madan N. Indian Pediatr; 2004 Jan 21; 41(1):21-7. PubMed ID: 14767084 [Abstract] [Full Text] [Related]
17. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy. Porter JB, Elalfy MS, Taher AT, Aydinok Y, Chan LL, Lee SH, Sutcharitchan P, Habr D, Martin N, El-Beshlawy A. Ann Hematol; 2013 Jan 21; 92(2):211-9. PubMed ID: 23086508 [Abstract] [Full Text] [Related]
18. Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients. Kontoghiorghes GJ. Expert Opin Drug Saf; 2008 Nov 21; 7(6):645-6. PubMed ID: 18983212 [Abstract] [Full Text] [Related]
19. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, Gattermann N, Giraudier S, Lee JW, Chan LL, Lin KH, Rose C, Taher A, Thein SL, Viprakasit V, Habr D, Domokos G, Roubert B, Kattamis A, EPIC Study Investigators. Haematologica; 2010 Apr 21; 95(4):557-66. PubMed ID: 19951979 [Abstract] [Full Text] [Related]
20. Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial. Premawardhena A, Perera C, Wijethilaka MN, Wanasinghe SK, Rajakaruna RHMG, Samarasinghe RANKK, Williams S, Mettananda S. BMJ Open; 2024 Feb 08; 14(2):e077342. PubMed ID: 38331857 [Abstract] [Full Text] [Related] Page: [Next] [New Search]